Aeglea BioTherapeutics (AGLE) News Today → I’m afraid WWIII is a very real possibility (From Porter & Company) (Ad) Free AGLE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative February 21, 2024 | benzinga.comNorthwest Biotherapeutics Stock (OTC:NWBO), Analyst Ratings, Price Targets, PredictionsJanuary 30, 2024 | wsj.comBridge Biotherapeutics Inc.December 7, 2023 | finance.yahoo.comSpyre Therapeutics Announces $180 Million Private PlacementNovember 27, 2023 | msn.comAeglea Biotherapeutics announces name change to Spyre TherapeuticsNovember 27, 2023 | markets.businessinsider.comAeglea BioTherapeutics Changes Name To Spyre Therapeutics; To Begin Trading Under Symbol SYRENovember 27, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBDNovember 9, 2023 | finance.yahoo.comAeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 30, 2023 | finance.yahoo.comAeglea BioTherapeutics to Participate in Upcoming November Investor ConferencesOctober 5, 2023 | msn.comAeglea BioTherapeutics (AGLE) Price Target Increased by 2435.71% to 18.11October 2, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Grants of Inducement AwardsSeptember 14, 2023 | finance.yahoo.comAeglea BioTherapeutics to Participate in Upcoming September ConferenceSeptember 14, 2023 | markets.businessinsider.comAeglea Biotherapeutics (AGLE) Gets a Buy from Stifel NicolausSeptember 8, 2023 | marketbeat.comAeglea BioTherapeutics (NASDAQ:AGLE) Cut to Sell at StockNews.comStockNews.com downgraded shares of Aeglea BioTherapeutics from a "hold" rating to a "sell" rating in a research report on Friday.September 8, 2023 | finanznachrichten.deAeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Announces Reverse Stock SplitSeptember 8, 2023 | marketbeat.comTrading was temporarily halted for "AGLE" at 09:09 AM with a stated reason of "LULD pause."September 7, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Reverse Stock SplitSeptember 5, 2023 | seekingalpha.comAeglea BioTherapeutics appoints Burrows as CFO, King-Jones as CLOSeptember 5, 2023 | markets.businessinsider.comAeglea BioTherapeutics Appoints Scott Burrows As Chief Financial OfficerSeptember 5, 2023 | finance.yahoo.comAeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-JonesAugust 16, 2023 | msn.comWells Fargo Maintains Aeglea BioTherapeutics (AGLE) Equal-Weight RecommendationAugust 11, 2023 | finanznachrichten.deAeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Reports Second Quarter 2023 Financial ResultsAugust 11, 2023 | finance.yahoo.comAeglea BioTherapeutics Reports Second Quarter 2023 Financial ResultsAugust 10, 2023 | fool.comAeglea BioTherapeutics (NASDAQ: AGLE)August 3, 2023 | msn.comAeglea BioTherapeutics (AGLE) Price Target Decreased by 54.54% to 1.45July 27, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica PharmaJuly 25, 2023 | seekingalpha.comAeglea initiated with Buy at Stifel citing potential in IBD spaceJuly 25, 2023 | msn.comStifel Initiates Coverage of Aeglea BioTherapeutics (AGLE) with Buy RecommendationJuly 25, 2023 | markets.businessinsider.comAeglea Biotherapeutics (AGLE) Initiated with a Buy at Stifel NicolausJune 26, 2023 | bizjournals.comFunding wrap: Former Dell Med dean raises $30MJune 23, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Grant of Inducement AwardsJune 23, 2023 | bizjournals.comM&A Wrap: Aeglea grabs another biotech co., $210M; Wealth manager acquiredJune 22, 2023 | proactiveinvestors.comAeglea BioTherapeutics stock skyrockets as it boosts inflammatory bowel disease portfolio with Spyre Therapeutics acquisitionJune 22, 2023 | investorplace.comWhy Is Aeglea BioTherapeutics (AGLE) Stock Up 392% Today?June 22, 2023 | marketwatch.comAeglea BioTherapeutics Shares Spike After Merger, New FundingJune 22, 2023 | benzinga.comAeglea BioTherapeutics Stock Surges Over 400% Today - What's Going OnMay 13, 2023 | finance.yahoo.comAeglea BioTherapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsMay 12, 2023 | msn.comRecap: Aeglea BioTherapeutics Q1 EarningsMay 12, 2023 | marketwatch.com10-Q: AEGLEA BIOTHERAPEUTICS, INC.May 11, 2023 | finance.yahoo.comAeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue EstimatesMay 11, 2023 | finanznachrichten.deAeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comAeglea BioTherapeutics Reports First Quarter 2023 Financial ResultsApril 13, 2023 | msn.comLifeSci Capital Downgrades Aeglea BioTherapeutics (AGLE)April 13, 2023 | msn.comJonesTrading Downgrades Aeglea BioTherapeutics (AGLE)April 13, 2023 | msn.comAeglea (AGLE) Plunges 26% After Rare Disorder Drug Study FailsApril 12, 2023 | msn.comWhy Are Aeglea BioTherapeutics Shares Sinking Today?April 12, 2023 | markets.businessinsider.comJonesTrading Sticks to Its Hold Rating for Aeglea Biotherapeutics (AGLE)April 12, 2023 | msn.comAeglea slumps ~25% as trial results trigger strategic options, workforce reductionApril 12, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic AlternativesMarch 17, 2023 | finance.yahoo.comAeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 7, 2023 | msn.comAeglea BioTherapeutics's Return On Capital Employed Insights Get Aeglea BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter. Email Address I’m afraid WWIII is a very real possibility (Ad)As one top U.S. cyber official claims: This [tech] is “the most powerful weapon of our time.” That's also why I've produced this new film. Take a look. AGLE Media Mentions By Week AGLE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGLE News Sentiment▼0.000.50▲Average Medical News Sentiment AGLE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGLE Articles This Week▼01▲AGLE Articles Average Week Get Aeglea BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: HCWB News Today RMTI News Today OCUP News Today CLNN News Today XLO News Today IMRX News Today AADI News Today SNSE News Today GANX News Today LEXX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AGLE) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin AnalyticsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMost important medical advance in 100 yearsThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceThe Presidential candidate you should REALLY be worried aboutStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeglea BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
